These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

995 related items for PubMed ID: 16968503

  • 1. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.
    Nista EC, Candelli M, Zocco MA, Cremonini F, Ojetti V, Finizio R, Spada C, Cammarota G, Gasbarrini G, Gasbarrini A.
    Am J Gastroenterol; 2006 Sep; 101(9):1985-90. PubMed ID: 16968503
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. 7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity.
    Antos D, Schneider-Brachert W, Bästlein E, Hänel C, Haferland C, Buchner M, Meier E, Trump F, Stolte M, Lehn N, Bayerdörffer E.
    Helicobacter; 2006 Feb; 11(1):39-45. PubMed ID: 16423088
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Levofloxacin-based triple therapy for first-line Helicobacter pylori eradication treatment: a multi-central, randomized, controlled clinical study].
    Cheng H, Hu FL, Zhang GX, Shi RH, Du YQ, Li ZS, Han W, Li YQ, Wu QD, Qian KD.
    Zhonghua Yi Xue Za Zhi; 2010 Jan 12; 90(2):79-82. PubMed ID: 20356486
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial.
    Kuo CH, Hu HM, Kuo FC, Hsu PI, Chen A, Yu FJ, Tsai PY, Wu IC, Wang SW, Li CJ, Weng BC, Chang LL, Jan CM, Wang WM, Wu DC.
    J Antimicrob Chemother; 2009 May 12; 63(5):1017-24. PubMed ID: 19246508
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia.
    Uygun A, Kadayifci A, Yesilova Z, Safali M, Ilgan S, Karaeren N.
    Clin Ther; 2008 Mar 12; 30(3):528-34. PubMed ID: 18405790
    [Abstract] [Full Text] [Related]

  • 10. Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics.
    de Bortoli N, Leonardi G, Ciancia E, Merlo A, Bellini M, Costa F, Mumolo MG, Ricchiuti A, Cristiani F, Santi S, Rossi M, Marchi S.
    Am J Gastroenterol; 2007 May 12; 102(5):951-6. PubMed ID: 17313499
    [Abstract] [Full Text] [Related]

  • 11. Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication.
    Molina-Infante J, Perez-Gallardo B, Fernandez-Bermejo M, Hernandez-Alonso M, Vinagre G, Dueñas C, Mateos-Rodriguez JM, Gonzalez-Garcia G, Abadia EG, Gisbert JP.
    Aliment Pharmacol Ther; 2010 May 12; 31(10):1077-84. PubMed ID: 20180787
    [Abstract] [Full Text] [Related]

  • 12. Preoperative versus postoperative Helicobacter pylori eradication therapy in gastric cancer patients: a randomized trial.
    Kim CG, Song HJ, Kook MC, Hong EK, Park S, Lee JY, Lee JH, Ryu KW, Kim YW, Bae JM, Choi IJ.
    Am J Gastroenterol; 2008 Jan 12; 103(1):48-54. PubMed ID: 17714557
    [Abstract] [Full Text] [Related]

  • 13. Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial.
    Georgopoulos S, Papastergiou V, Xirouchakis E, Laoudi F, Lisgos P, Spiliadi C, Papantoniou N, Karatapanis S.
    J Clin Gastroenterol; 2013 Mar 12; 47(3):228-32. PubMed ID: 22858517
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study.
    Assem M, El Azab G, Rasheed MA, Abdelfatah M, Shastery M.
    Eur J Intern Med; 2010 Aug 12; 21(4):310-4. PubMed ID: 20603042
    [Abstract] [Full Text] [Related]

  • 15. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
    Molina-Infante J, Pazos-Pacheco C, Vinagre-Rodriguez G, Perez-Gallardo B, Dueñas-Sadornil C, Hernandez-Alonso M, Gonzalez-Garcia G, Mateos-Rodriguez JM, Fernandez-Bermejo M, Gisbert JP.
    Helicobacter; 2012 Aug 12; 17(4):269-76. PubMed ID: 22759326
    [Abstract] [Full Text] [Related]

  • 16. Levofloxacin-containing triple and sequential therapy or standard sequential therapy as the first line treatment for Helicobacter pylori eradication in China.
    Qian J, Ye F, Zhang J, Yang YM, Tu HM, Jiang Q, Shang L, Pan XL, Shi RH, Zhang GX.
    Helicobacter; 2012 Dec 12; 17(6):478-85. PubMed ID: 23067317
    [Abstract] [Full Text] [Related]

  • 17. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients.
    Gisbert JP, Bermejo F, Castro-Fernández M, Pérez-Aisa A, Fernández-Bermejo M, Tomas A, Barrio J, Bory F, Almela P, Sánchez-Pobre P, Cosme A, Ortiz V, Niño P, Khorrami S, Benito LM, Carneros JA, Lamas E, Modolell I, Franco A, Ortuño J, Rodrigo L, García-Durán F, O'Callaghan E, Ponce J, Valer MP, Calvet X, H. pylori Study Group of the Asociación Española de Gastroenterología.
    Am J Gastroenterol; 2008 Jan 12; 103(1):71-6. PubMed ID: 17764498
    [Abstract] [Full Text] [Related]

  • 18. Randomized comparison of two rescue therapies for Helicobacter pylori infection.
    Wu DC, Hsu PI, Chen A, Lai KH, Tsay FW, Wu CJ, Lo GH, Wu JY, Wu IC, Wang WM, Tseng HH.
    Eur J Clin Invest; 2006 Nov 12; 36(11):803-9. PubMed ID: 17032348
    [Abstract] [Full Text] [Related]

  • 19. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
    Köksal AS, Parlak E, Filik L, Yolcu OF, Odemiş B, Ulker A, Saşmaz N, Ozden A, Sahin B.
    J Gastroenterol Hepatol; 2005 Apr 12; 20(4):637-42. PubMed ID: 15836716
    [Abstract] [Full Text] [Related]

  • 20. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen.
    Rokkas T, Sechopoulos P, Robotis I, Margantinis G, Pistiolas D.
    Am J Gastroenterol; 2009 Jan 12; 104(1):21-5. PubMed ID: 19098844
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.